CORPORATE OVERVIEW

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases.

Regeneron is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to eight FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary *VelociSuite*® technologies, such as *VelocImmune*®, which uses a unique genetically-humanized mouse to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center®, which is conducting one of the largest genetics sequencing efforts in the world.

GENERAL COMPANY INFORMATION

– Founded in 1988: Publicly traded company (NASDAQ: REGN) since 1991
– More than 8,900 employees in the U.S., UK and EU
– 2019 R&D investment of nearly $2.5 billion

LOCATIONS

– Tarrytown, NY: Corporate and Research & Development headquarters
– Rensselaer, NY and Limerick, Ireland: Large-scale biologics Industrial Operations and Product Supply (IOPS) facilities
– Sleepy Hollow, NY, Basking Ridge, NJ, and Washington, D.C.: Satellite offices
– Dublin, Ireland and London, UK: Global business offices

LEADERSHIP TEAM

– **Leonard S. Schleifer, MD, PhD**
Co-Founder, President and Chief Executive Officer

– **George D. Yancopoulos, MD, PhD**
Co-Founder, President and Chief Scientific Officer
+ *Member, National Academy of Sciences*

– **P. Roy Vagelos, MD**
Chairman of the Board
+ *Former Chief Executive Officer and Chairman of the Board, Merck & Co.*
+ *Member, National Academy of Sciences*

– **Board of Directors** includes two Nobel Laureates and seven members of the National Academy of Sciences

FDA-APPROVED & MARKETED MEDICINES

Arcalyst®
(rilonacept)
Injection for Subcutaneous Use

**DUPIXENT**
(dupilumab) Injection
200mg · 300mg

EYLEA®
(aflibercept) Injection

KEVZARA®
(sarilumab) injection
150 mg | 200 mg
Please see Full Prescribing Information including Boxed WARNING at www.kevzara.com

Praluent®
(alirocumab) Injection 75mg/mL 150mg/mL

Inmazeb™
(atoltivimab, maftivimab, and odesivimab – ebgn)
Injection
16.67 mg / 16.67 mg / 16.67 mg per mL

LIBTAYO®
(cemiplimab-rwlc)
Injection 350 mg

* U.S. Food and Drug Administration

CLINICAL PRODUCT CANDIDATES

PHASE 1 → **PHASE 2** → **PHASE 3**

PHASE 1

CEMIPLIMAB*
PD-1 Antibody | Cancer

REGN3767
LAG-3 Antibody | Cancer

REGN6569
GITR Antibody | Cancer

ODRONEXTAMAB
CD20 X CD3 Antibody | Cancer

REGN4018*
MUC16 X CD3 Antibody | Cancer

REGN5459*
BCMA X CD3 Antibody | Cancer

REGN5678
PSMA X CD28 Antibody | Cancer

REGN5093
MET X MET Antibody | Cancer

REGN5713-5714-5715
Bet v 1 Antibodies | Birch allergy

REGN7257
IL2Rg Antibody | Aplastic anemia

CASIRIVIMAB + IMDEVIMAB
SARS-CoV2 Virus Multi-Antibody Therapy
Multi-dose safety study in healthy volunteers

REGN5381
NPR1 Agonist Antibody
Heart failure

PHASE 2

AFLIBERCEPT
VEGF-Trap
High dose (8mg) for wet age-related macular degeneration (AMD)

CEMIPLIMAB*
PD-1 Antibody
Basal cell carcinoma (BCC), metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC), neoadjuvant CSCC

ODRONEXTAMAB
CD20 X CD3 Antibody
B-cell non-Hodgkin lymphoma

REGN5458*
BCMA X CD3 Antibody | Multiple myeloma

SARILUMAB*
IL-6R Antibody
Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis

DUPILUMAB*
IL-4R Antibody
Peanut allergy, grass allergy

REGN1908-1909
Fel d 1 Multi-Antibody Therapy
Cat allergy

ITEPEKIMAB*
IL-33 Antibody
Asthma, chronic obstructive pulmonary disease (COPD)

EVINACUMAB
ANGPTL-3 Antibody
Refractory hypercholesterolemia (both HeFH and non-FH), severe hypertriglyceridemia

POZELIMAB
C5 Antibody
Paroxysmal nocturnal hemoglobinuria, CD-55 deficient protein-losing enteropathy

REGN4461
LEPR Agonist Antibody
Generalized lipodystrophy

GARETOSMAB
Activin-A Antibody
Fibrodysplasia Ossificans Progressiva (FOP)

PHASE 3

AFLIBERCEPT
VEGF-Trap
Retinopathy of prematurity (ROP), high-dose formulation (8mg) for wet age-related macular degeneration (AMD) and diabetic macular edema (DME)

CEMIPLIMAB*
PD-1 Antibody
Non-small cell lung cancer (NSCLC), cervical cancer, adjuvant cutaneous squamous cell carcinoma (CSCC)

DUPILUMAB*
IL-4R Antibody
Atopic dermatitis in pediatric patients 6 mo.–11 y.o., asthma in pediatric patients 6-11 y.o., eosinophilic esophagitis in patients 6 and older, chronic obstructive pulmonary disease (COPD), bullous pemphigoid, prurigo nodularis, chronic spontaneous urticaria, allergic bronchopulmonary aspergillosis

CASIRIVIMAB + IMDEVIMAB
SARS-CoV2 Virus
Multi-Antibody Therapy
Treatment and prevention of COVID-19

ALIROCUMAB
PCSK9 Antibody
Homozygous familial hypercholesterolemia (HoFH) in adults and pediatrics, heterozygous familial hypercholesterolemia (HeFH) in pediatrics

EVINACUMAB
ANGPTL-3 Antibody
Homozygous familial hypercholesterolemia (HoFH)

FASINUMAB†
NGF Antibody
Osteoarthritis pain of the knee or hip

■ OPHTHALMOLOGY ● ONCOLOGY ■ IMMUNOLOGY & INFLAMMATORY DISEASES ■ INFECTIOUS DISEASES ■ CARDIOVASCULAR/METABOLIC DISEASES ■ RARE DISEASES ■ PAIN

* IN COLLABORATION WITH SANOFI
† IN COLLABORATION WITH TEVA AND MITSUBISHI TANABE

This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

LEADERS IN TECHNOLOGY

– **Fully human monoclonal antibodies:** Regeneron has developed a suite of patented technologies (*VelociSuite®*), including *VelociGene®*, *VelocImmune®* and *VelociMab®*, that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high quality, fully human antibodies as drug candidates.

– **Fusion proteins:** Our novel and patented "Trap" fusion protein technology creates high-affinity product candidates for many different types of signaling molecules, including growth factors and cytokines. The technology involves fusing two distinct fully human receptor components and a fully human immunoglobulin.

– **Regeneron Genetics Center®:** A large-scale, fully-integrated genomics program that uses DNA sequencing and analysis to better understand the causes of disease, and to more rapidly and efficiently bring new therapeutics to patients in need.

Science: Top Employer, 2020
Fortune: Change the World, 2020
Forbes: JUST Companies, 2020
Fortune: Best Companies to Work For, 2020
Newsweek: America's Most Responsible Companies, 2020
Fast Company: Best Workplaces for Innovators, 2020
Dow Jones Sustainability World Index, 2020
Dow Jones Sustainability North America Index, 2020

★ AWARDS

Civic 50: Most Community-Minded Companies in the Nation, 2020
Great Places to Work: Best Workplace in Ireland, 2020
IDEA Pharma: Pharmaceutical Invention Index, 2019
Harvard Business Review: Best Performing CEOs, 2019
Shingo Institute: The Shingo Prize, 2019
Forbes: Top 10 Most Innovative Companies, 2018

To learn more about us, please visit:

REGENERON.COM 🐦 **@REGENERON**

REGENERON